Elanco

Overview
Activities
News

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets.

Founded in 1954 as part of Eli Lilly and Company, Elanco became an independent public company in 2018. The company develops, manufactures and markets health products for pets and farm animals, including vaccines, parasiticides, antibiotics, dermatology treatments, pain medications, and feed additives. Elanco operates in over 90 countries and had revenue of USD 4.42 billion in 2023.

Elanco's business is divided into two main segments: Pet Health and Farm Animal. The Pet Health segment offers products for companion animals like dogs and cats, including parasiticides such as the Advantage family of products and Seresto flea and tick collars. The Farm Animal segment provides products for livestock and poultry, including vaccines, antibiotics, and feed additives like Rumensin for cattle. Elanco has a robust pipeline of new products in development, including potential blockbuster treatments for canine dermatology and parasites, as well as a feed additive to reduce methane emissions from cattle. In February 2024, the company announced plans to divest its aqua business to Merck for USD 1.3 billion to focus on its core pet and livestock segments.

HQ Location:
2500 Innovation Way Greenfield IN USA
Founded year:
1954
Employees:
10,000+
Animal Therapeutics
Animal Therapeutics
Livestock Biotech
Livestock Biotech
Loading...

EDGE Insights

arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.